

Serge Evrard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7690392/publications.pdf>

Version: 2024-02-01

23
papers

512
citations

759233

12
h-index

677142

22
g-index

39
all docs

39
docs citations

39
times ranked

732
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Ablation and Resection (CARE) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases. PLoS ONE, 2014, 9, e114404.	2.5	63
2	Use of Bioresorbable Membranes to Reduce Abdominal and Perihepatic Adhesions in 2-Stage Hepatectomy of Liver Metastases From Colorectal Cancer. Annals of Surgery, 2013, 258, 30-36.	4.2	59
3	Cytoreductive Surgery of Colorectal Peritoneal Metastases: Outcomes after Complete Cytoreductive Surgery and Systemic Chemotherapy Only. PLoS ONE, 2015, 10, e0122816.	2.5	44
4	Parenchymal sparing surgery brings treatment of colorectal liver metastases into the precision medicine era. European Journal of Cancer, 2018, 104, 195-200.	2.8	37
5	Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer. Cancer Research, 2019, 79, 5008-5021.	0.9	34
6	The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Oncogene, 2020, 39, 3571-3587.	5.9	34
7	What can we learn from oncology surgical trials?. Nature Reviews Clinical Oncology, 2016, 13, 55-62.	27.6	29
8	Proprotein convertases: Key players in inflammation-related malignancies and metastasis. Cancer Letters, 2020, 473, 50-61.	7.2	29
9	ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activation. JCI Insight, 2020, 5, .	5.0	25
10	Autopsy of an expert consensus: End of hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis. European Journal of Surgical Oncology, 2018, 44, 1845-1846.	1.0	22
11	The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression. Frontiers in Immunology, 2022, 13, 850856.	4.8	20
12	From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern. Annals of Surgery, 2016, 264, 911-912.	4.2	19
13	Regulation of the proprotein convertases expression and activity during regenerative angiogenesis: Role of hypoxia-inducible factor (HIF). European Journal of Cell Biology, 2017, 96, 457-468.	3.6	16
14	HIPEC: standard of care or an experimental approach?. Lancet Oncology, The, 2012, 13, e462-e463.	10.7	12
15	Parenchymal sparing surgery for colorectal liver metastases: The need for a common definition. European Journal of Surgical Oncology, 2017, 43, 2285-2291.	1.0	10
16	Furin Prodomain ppFurin Enhances Ca ²⁺ Entry Through Orai and TRPC6 Channelsâ€™ Activation in Breast Cancer Cells. Cancers, 2021, 13, 1670.	3.7	10
17	Role of Furin in Colon Cancer Stem Cells Malignant Phenotype and Expression of LGR5 and NANOG in KRAS and BRAF-Mutated Colon Tumors. Cancers, 2022, 14, 1195.	3.7	9
18	Open versus laparoscopy-assisted colectomy. Lancet, The, 2003, 361, 73.	13.7	8

#	ARTICLE	IF	CITATIONS
19	Collaboration between EORTC and JCOG – how to accelerate global clinical research partnership. Japanese Journal of Clinical Oncology, 2017, 47, 164-169.	1.3	7
20	Response to Faitot et al – Two-stage Hepatectomy Versus 1-Stage Resection Combined With Radiofrequency for Bilobar Colorectal Metastases. Annals of Surgery, 2017, 265, e52-e53.	4.2	3
21	Limits of Colorectal Liver Metastases Resectability: How and Why to Overcome Them?. Recent Results in Cancer Research, 2014, 203, 213-229.	1.8	2
22	Survival after resection plus intra-operative radiofrequency ablation (IRFA) to treat colorectal liver metastases (CLM): Results of an international collaborative study.. Journal of Clinical Oncology, 2013, 31, 3558-3558.	1.6	2
23	Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial. BMC Research Notes, 2019, 12, 450.	1.4	1